Neprilysin in Heart Failure: From Oblivion to Center Stage

JACC: Heart Failure

Volumn 3, Issue 8, 2015, Pages 637-640

  Bayés Genís, Antoni ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

BNP; Heart failure; Neprilysin; Physiology

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT; SACUBITRIL PLUS VALSARTAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADVERSE OUTCOME; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; ENZYME ACTIVITY; ENZYME ANALYSIS; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; BLOOD;

BIOMARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS;

EID: 84939427586     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.03.010     Document Type: Editorial

References (6)

1. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920-926.
2. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004. for the PARADIGM-HF Investigators and Committees.
3. Vodovar N., Séronde M.-F., Laribi S., et al. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. J Am Coll Cardiol HF 2015, 3:629-636.
4. Packer M., McMurray J.J., Desai A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015, 131:54-61. for the PARADIGM-HF Investigators and Coordinators.
5. Bayes-Genis A., Barallat J., Galan A., et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 2015, 65:657-665.
6. Bayes-Genis A., Barallat J., Pascual D., et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. J Am Coll Cardiol HF 2015, 3:641-644.